Financial guidance 2018
MorphoSys expects Group revenues for the 2018 financial year in the range of EUR 20 to 25 million. R&D expenses for proprietary drug development are expected to amount to EUR 95 to 105 million. The Company expects earnings before interest and taxes (EBIT) in a range of between EUR -110 to -120 million. This guidance does not include revenues from potential future partnerships or licensing agreements or milestone payments for MOR103 or MOR202 that could occur in the course of 2018. Effects from potential in-licensing or co-development deals for new development candidates are also not included in the guidance.
|in € million||
|Group Revenues||20 to 25||66.8|
|R&D expenses Proprietary Development||95 to 105||99.1|
|Group EBIT||-110 to -120||- 67.6|